Supplementary Figure 4 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Tetsuya Mitsudomi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
1022Publications signalées
62259Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesHER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Publications récentes
Supplementary Figure 2 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Supplementary Figure 3 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Supplementary Figure 1 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Supplementary Figure 6 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Data from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Supplementary Figure 5 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Supplementary Table 1 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC
Atsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, Koichi Azuma et autres
0 citations
Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer
David Harpole, John V. Heymach, Martin Reck, Janis Taube et autres
0 citationsJournal of Thoracic and Cardiovascular Surgery
Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial
John V. Heymach, Jie He, David Harpole, Tetsuya Mitsudomi et autres
0 citationsJournal of Clinical Oncology
Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer
Tetsuya Mitsudomi, Makoto Nishio, Kazuhiko Nakagawa, Nobuyuki Yamamoto et autres
0 citationsInternational Journal of Lung Cancer
Immunotherapy in resectable non–small cell lung cancer; emerging clinical questions
Tetsuya Mitsudomi, Katsuaki Sato, Kenichi Suda, Kenji Tomizawa
0 citationsInternational Journal of Lung Cancer
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.